Impacto 2.0: Mobile Smoking Cessation Across Texas
Impacto 2.0: Addressing Disparities in Smoking Cessation Access and Outcomes for Hispanic Adults Who Smoke in Texas
This is a preliminary efficacy trial that will examine whether Impacto 2.0 produces higher rates of biochemically verified smoking abstinence among Hispanic adults across Texas compared to the NCI quitSTART app. The primary objective is to evaluate the preliminary efficacy of Impacto 2.0 in reducing smoking, tobacco withdrawal, and craving. One hundred Hispanic adults who smoke will be recruited across Texas and followed remotely over an 8-week intervention period with a 3-month post-quit follow-up.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
This project proposes a preliminary efficacy randomized clinical trial (RCT) testing Impacto 2.0, a culturally adapted, bilingual (Spanish and English), smartphone-based smoking cessation intervention developed and pilot tested among Hispanic adults who smoke.
Impacto was originally developed through a National Institutes of Health (NIH)-funded Phase 1 Small Business Technology Transfer (STTR) project using a community-informed, user-centered design process that integrated input from Hispanic end-users, bilingual developers, and clinical providers serving a predominantly Hispanic population. The app targets anxiety sensitivity (AS), or the fear of anxiety-related bodily sensations, which has been empirically shown to be a robust, modifiable transdiagnostic mechanism that impedes smoking cessation success among Hispanic adults.
In a proof-of-concept open trial of Impacto 1.0, 65.4% of Spanish-speaking Hispanic adult participants reported smoking abstinence at 4 weeks post-quit, with significant reductions in anxiety sensitivity and high rates of feasibility, acceptability, and engagement observed across the sample.
The present project aims to extend Impacto 2.0 to Hispanic adults who smoke across Texas, with a statewide targeted recruitment emphasis on rural and medically underserved regions. These regions include communities where geographic, linguistic, and economic barriers may limit access to evidence-based smoking cessation treatment. By leveraging smartphone-based delivery, the study seeks to increase access to culturally adapted smoking cessation support while evaluating the preliminary efficacy of Impacto 2.0 compared to the National Cancer Institute's (NCI) quitSTART app.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Michael J Zvolensky, Ph.D.
- Número de telefone: 713-743-8056
- E-mail: mjzvolen@Central.UH.EDU
Locais de estudo
-
-
Texas
-
Houston, Texas, Estados Unidos, 77204
- RESTORE Laboratory: Research on Emotion, Substance Treatment Outcomes, Rehabilitation, and Empowerment
-
Contato:
- Angelica G. Duran, B.S
- Número de telefone: 713-743-8056
- E-mail: agduran@cougarnet.uh.edu
-
Investigador principal:
- Micheal J Zvolensky, Ph.D.
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Self-identifies as Hispanic/Latino/a
- Currently resides in Texas
- Age 18 years or older
- Currently smokes combustible cigarettes daily, biochemically verified by expired carbon monoxide >7 ppm using the CoVita iCOquit Smokerlyzer
- Meets criteria for elevated anxiety sensitivity (cut-off score of 5 on the Short Scale Anxiety Sensitivity Index)
- Motivated to quit smoking
- Able to provide informed consent
- Has daily access to an iPhone or Android smartphone
- Fluent in English or Spanish
Exclusion Criteria:
- Current use of vaping/e-cigarettes, cigars, cigarillos, pipes, cannabis products, or other nicotine/tobacco products in addition to combustible cigarettes
- Current participation in alcohol or drug-use treatment, including smoking-cessation treatment
- Current psychotherapy for anxiety or depression
- Concurrent use of medication for anxiety or depression
- Active suicidality (ideation, intent, and/or plan)
- Current psychosis
- Currently pregnant, nursing, or actively trying to conceive, including male participants who report that they or a partner are actively trying to conceive
- Myocardial infarction within the past 2 weeks
- Uncontrolled high blood pressure
- Participants with the ability to become pregnant must provide a negative urine pregnancy test before final eligibility/onboarding
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Impacto 2.0
Participants will use the Impacto 2.0 smartphone application for 8 weeks. |
A culturally adapted, bilingual smartphone-based smoking cessation intervention that provides psychoeducation targeting anxiety sensitivity reduction. The app includes four lessons per week across the 8-week intervention period and exercises targeting anxiety sensitivity. |
|
Comparador Ativo: quitSTART
Participants will use the National Cancer Institute's quitSTART smartphone application for 8 weeks. |
The National Cancer Institute's quitSTART smartphone smoking cessation application. The app provides tools to help users understand smoking patterns, track smoking habits and urges, and manage cravings. |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Biochemically Verified 7-Day Point Prevalence Smoking Abstinence
Prazo: Week 8
|
Smoking abstinence will be assessed using self-reported 7-day point prevalence abstinence and biochemically verified using the CoVita iCOquit Smokerlyzer. An expired carbon monoxide level <7 ppm will indicate abstinence. |
Week 8
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Biochemically Verified 7-Day Point Prevalence Smoking Abstinence
Prazo: Week 16
|
Smoking abstinence will be assessed using self-reported 7-day point prevalence abstinence and biochemically verified using the CoVita iCOquit Smokerlyzer. An expired carbon monoxide level <7 ppm will indicate abstinence. |
Week 16
|
|
Tobacco Withdrawal
Prazo: Baseline, Week 4, Week 8, and Week 16
|
Tobacco withdrawal will be assessed using the revised 15-item Minnesota Nicotine Withdrawal Scale (MNWS), a self-report questionnaire measuring smoking withdrawal symptoms. Items are rated on a 5-point Likert scale ranging from 0 (none) to 4 (severe). A withdrawal severity score is calculated by averaging the core withdrawal symptom items, yielding a score ranging from 0 to 4, with higher scores indicating greater tobacco withdrawal severity. |
Baseline, Week 4, Week 8, and Week 16
|
|
Tobacco Craving
Prazo: Baseline, Week 4, Week 8, and Week 16
|
Tobacco craving will be assessed using the 10-item Questionnaire of Smoking Urges-Brief (QSU-B), which measures cigarette craving in the current moment. Items are rated on a 7-point Likert scale ranging from 1 (strongly disagree) to 7 (strongly agree). The total score is calculated by summing all 10 items, with possible scores ranging from 10 to 70. Higher scores indicate greater cigarette craving. |
Baseline, Week 4, Week 8, and Week 16
|
|
Anxiety Sensitivity
Prazo: Baseline, Week 4, Week 8, and Week 16
|
Anxiety sensitivity will be assessed using the 5-item Short Scale Anxiety Sensitivity Index (SSASI), which measures fear of anxiety-related bodily sensations. Items are rated on a 5-point Likert scale ranging from 0 (very little) to 4 (very much). The total score is calculated by summing all five items, with possible scores ranging from 0 to 20. Higher scores indicate greater anxiety sensitivity. |
Baseline, Week 4, Week 8, and Week 16
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- STUDY00006201
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
There is no plan to make individual participant data (IPD) available to other researchers.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .